Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Daniel Bradbury is Director at Castle Biosciences. OQRO lists 34 transactions filed with the SEC under this name, the latest on Jul 28, 2026, each linked to the official Form 4.
Director
Disclosures on record
34
Companies involved
3
As of the latest filing on , Daniel Bradbury reported holding 5,700 shares of Castle Biosciences (CSTL), worth about $193K at the last close of $34 (Nov 13, 2026), held through an annette bradbury irrecovable descendant's trust, a daniel bradbury irrecovable descendant's trust.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Castle Biosciences CSTL | 5,700 | 2,850 annette bradbury irrecovable descendant's trust · 2,850 daniel bradbury irrecovable descendant's trust | $34 | $193K | Dec 3, 2024 |
Is this Daniel Bradbury’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Vivani MedicalVANI
3 disclosures · Jan 2026 – Jul 2026
Jul 27, 20267,965disclosed Jul 28
DetailsOfficial recordJun 24, 202637Kdisclosed Jun 25
DetailsOfficial recordJan 1, 202647Kdisclosed Jan 5
DetailsOfficial recordMay 28, 202670Kdisclosed May 30
DetailsOfficial recordCastle BiosciencesCSTL
30 disclosures · Oct 2024 – Feb 2025 · 30 sold
Feb 5, 2025Sold~$141Kdisclosed Feb 7
DetailsOfficial recordFeb 5, 2025Sold~$40Kdisclosed Feb 7
DetailsOfficial recordFeb 5, 2025Sold~$40Kdisclosed Feb 7
DetailsOfficial recordJan 6, 2025Sold~$89Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$43Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$25Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$25Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$14Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$12Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$12Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$4Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$4Kdisclosed Jan 8
DetailsOfficial recordDec 3, 2024Sold~$145Kdisclosed Dec 5
DetailsOfficial recordDec 3, 2024Sold~$41Kdisclosed Dec 5
DetailsOfficial recordDec 3, 2024Sold~$41Kdisclosed Dec 5
DetailsOfficial recordDec 3, 2024Sold~$11Kdisclosed Dec 5
DetailsOfficial recordDec 3, 2024Sold~$3.1Kdisclosed Dec 5
DetailsOfficial recordDec 3, 2024Sold~$3.1Kdisclosed Dec 5
DetailsOfficial recordNov 1, 2024Sold~$94Kdisclosed Nov 5
DetailsOfficial recordNov 1, 2024Sold~$45Kdisclosed Nov 5
DetailsOfficial recordNov 1, 2024Sold~$36Kdisclosed Nov 5
DetailsOfficial recordNov 1, 2024Sold~$27Kdisclosed Nov 5
DetailsOfficial recordNov 1, 2024Sold~$27Kdisclosed Nov 5
DetailsOfficial recordNov 1, 2024Sold~$13Kdisclosed Nov 5
DetailsOfficial recordNov 1, 2024Sold~$13Kdisclosed Nov 5
DetailsOfficial recordNov 1, 2024Sold~$10Kdisclosed Nov 5
DetailsOfficial recordNov 1, 2024Sold~$10Kdisclosed Nov 5
DetailsOfficial recordOct 7, 2024Sold~$148Kdisclosed Oct 9
DetailsOfficial recordOct 7, 2024Sold~$42Kdisclosed Oct 9
DetailsOfficial recordOct 7, 2024Sold~$42Kdisclosed Oct 9
DetailsOfficial recordDaniel Bradbury bought shares on the open market in 2012 and 2014, and has not bought since 2014 across 4 companies. Sales in each of the last 6 years.
Daniel Bradbury reported 5 open-market purchases and 631 sales since 2008; purchases in 2 different years, most recently 2014.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $451K12×12 trades |
| 2024 | — | $3.61M56×56 trades |
| 2023 | — | $4.42M71×71 trades |
| 2022 | — | $7.24M56×56 trades |
| 2021 | — | $135M162×162 trades |
| 2020 | — | $9.02M76×76 trades |
| 2017 | — | $485K8×8 trades |
| 2016 | — | $1.23M21×21 trades |
| 2015 | — | $4M44×44 trades |
| 2014 | $499K3×3 trades | $6.85M77×77 trades |
| 2012 | $249K2×2 trades | — |
| 2011 | — | $1.45M11×11 trades |
| 2010 | — | $2.04M16×16 trades |
| 2009 | — | $889K14×14 trades |
| 2008 | — | $990K7×7 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Dec 3, 2024, Daniel Bradbury reported holding 5,700 shares of Castle Biosciences (CSTL), held indirectly. At the last close of $34 on Nov 13, 2026, that is about $193K. This is the stake disclosed in filings, not a net worth.
Daniel Bradbury bought shares on the open market in 2012 and 2014, and has not bought since 2014 across 4 companies. Sales in each of the last 6 years.
In SEC filings since 2008: the latest open-market purchase is from 2014; the latest open-market sale is from 2025.
4 companies: Castle Biosciences (CSTL, 2020–2025), Illumina, Inc. (ILMN, 2008–2017), Corcept Therapeutics (CORT, 2012–2015), Geron (GERN, 2014).
Daniel Bradbury reported 0 open-market purchases and 433 sales here, 2020 to 2025.
Daniel Bradbury reported 0 open-market purchases and 186 sales here, 2008 to 2017.
Daniel Bradbury reported 4 open-market purchases and 12 sales here, 2012 to 2015.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
